In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Vivo's Deals Of The Month, January 2017

Executive Summary

In Vivo's editors pick January's most significant deals, including J&J's Actelion acquisition and a big launch for Vir Biotechnology. (Article free with registration.)

Top Alliance: Biogen Pays To Protect Tecfidera

Biogen Inc. is paying $1.25 billion up front in exchange for a license to all intellectual property owned by Denmark's Forward Pharma AS in the US. Biogen will pay royalties on net sales of any of its multiple sclerosis therapies covered by a Forward Pharma patent and that contain dimethyl fumarate, one of which is Tecfidera – Biogen's biggest revenue generator with $4 billion in sales for 2016. Royalty payments could spiral if Forward wins a series of ongoing patent disputes with Biogen. [See Deal]

Top Financing: Vir's Infectious Ambitions

Vir Biotechnology Inc. launched with a commitment for at least $150 million in Series A money. Arch Venture Partners and the Bill & Melinda Gates Foundation led the round. Vir says it will use "breakthroughs in immune programming" to create cures, therapies and preventive medicine for infectious diseases. In addition to in-house R&D, Vir plans to fund academic research and to build its pipeline through in-licensing. Former Biogen CEO George Scangos is heading the start-up, which has already done one deal: acquiring TomegaVax Inc. to obtain its viral vectors. [See Deal]

Top M&A: J&J/Actelion: Win-Win-Win

Johnson & Johnson's months-long pursuit of Actelion Pharmaceuticals Ltd. culminated in a $30 billion cash acquisition on January 26. J&J gets immediate access to the Swiss biotech's lucrative pulmonary arterial hypertension franchise and late-stage pipeline as well as initial 16% ownership in a new spin-out formed around Actelion's drug discovery operations and early-stage clinical assets. J&J has rights to an additional 16% of the new company, which will be based and listed in Switzerland and headed by Actelion co-founder and CEO Jean-Paul Clozel, MD.[See Deal][See Deal]

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts